Wayne Paterson


Wayne has held numerous, senior positions in multi-national companies. Throughout his career, he has been responsible for building businesses throughout the world, as well as mergers and major restructures. From 2007 to 2013, he held senior positions at Merck Serono. In his most recent position as President of Europe, Canada and Australia, he managed over $3 billion in sales with an operational budget of $500 million. Wayne also held the position of Global Head of Cardio Metabolic Care and General Medicine, with revenue responsibility of $1.5 billion, and was responsible for all aspects of company strategy, including manufacturing strategies, commercial operations and budgets. Between 2010 and 2012, he was Head of Emerging Markets including Russia, China, India and Brazil, and was a member of the Executive Board. As President during 2007 until 2010 in Japan, Wayne created Merck Serono Japan and successfully managed all company divisions, launching several major products. Between 1994 and 2005, he was employed by Roche Pharmaceuticals. As Marketing Director in Shanghai, China, he launched eight products during this time, including cardiovascular products. Wayne is an Australian national and has resided overseas since 1999, having lived in China, Singapore, Korea, Japan, Switzerland and the US. He now lives in Switzerland, where he is CEO and co-founder of a software company that provides solutions to the global pharmaceutical industry. Wayne is also a Non-Executive Director of Cepheid (NASDAQ CHPD) a molecular diagnostics company based in California. Wayne holds an MBA from the University of Southern Queensland, and a degree in business studies from the Queensland University of Technology. He has also studied business courses at North Western University (Kellog School of Management) in Chicago, IMD Business School in Switzerland, INSEAD in France and Hong Kong University of Technology.

John Seaberg


Between 2007 and 2014, John Seaberg was Founder, Chairman and CEO of NeoChord Inc, a venture capital-backed company commercialising technology developed at the Mayo Clinic for the repair of the mitral valve via minimally invasive techniques. Previously, he was employed by Guidant Corp from 1996 until 2006. During ten years at Guidant, he served in various executive level positions in sales and marketing, including Director of Bradycardia Marketing for Cardiac Rhythm Management (CRM) and Vice President of Sales for Cardiac Surgery, in which he managed a field sales team of more than 600 people and over $1 billion in revenue. In 1991, John became a co-founder of ACIST Medical and served as its first President and CEO. He was also the founder and CEO of Seaberg Medical, a regional distributor of implantable cardiovascular devices. He served on the board of publicly traded Synovis Life Technologies (SYNO) from 2008 until its sale to Baxter Inc in 2012. Currently, John is Executive Vice President of Cedar Point Capital, a boutique investment banking firm in Minneapolis, Mn. USA. He is Chairman of Medicom Health Interactive and also Chairman of Phraxis Inc. which are both private healthcare companies. He lives in the US and holds a Bachelor of Arts in Speech Communications from the University of Minnesota and a Masters in Business Administration (MBA) from the Carlson School of Management, also at the University of Minnesota.

Mathew Ratty


Mathew Ratty is the co-founder of MC Management Group Pty Ltd, a long-only venture capital firm operating in the debt and equity space both domestically and internationally. Mathew also holds the role of Head of Investment and is responsible for negotiating deal structures and asset pricing for companies in the healthcare, financials and technology equities space. Throughout his time with MC Management, Mathew has achieved standout high returns (alpha) against the S&P 500 and also successfully managed multiple seed investments leading to over 250% returns for the company. From 2009-2013, Mathew worked as an analyst at Gladstone Bridge Pty Ltd, a property development and equity company. Based on his successful role, Mathew joined Gladstone as a Director, overseeing the asset allocation of the company. Mathew holds a Bachelor of Commerce degree (Property and Finance) with first class honours in Finance from Curtin University of Technology.

Simon Buckingham


Simon has more than 25 years’ experience in the global pharmaceutical industry across a range of functions and a variety of therapeutic areas. Based in Sydney, Simon is a senior global advisor to Actelion, one of the world’s leading biopharmaceutical companies, and is a director of Actelion Australia. He was President, Global Corporate and Business Development at Actelion from 2005-2011, a position which spanned licensing, M&A, alliance management and corporate strategic planning. Simon served as President, North America and Asia-Pacific at Actelion from 2000-2005, with responsibility for all commercial operations in the region. He was the founding President of Actelion Pharmaceuticals US.